

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): **June 10, 2010**

BioTime, Inc.

(Exact name of registrant as specified in its charter)

California

(State or other jurisdiction of
incorporation)

1-12830

(Commission File Number)

94-3127919

(IRS Employer
Identification No.)

**1301 Harbor Bay Parkway
Alameda, California 94502**

(Address of principal executive offices)

(510) 521-3390

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Statements made in this Report that are not historical facts may constitute forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed. Such risks and uncertainties include but are not limited to those discussed in this report and in BioTime's other reports filed with the Securities and Exchange Commission. Words such as "expects," "may," "will," "anticipates," "intends," "plans," "believes," "seeks," "estimates," and similar expressions identify forward-looking statements.

Section 5 – Corporate Governance and Management

Item 5.07 - Submission of Matters to a Vote of Security Holders.

Our annual meeting of shareholders was held on June 10, 2010. At the meeting our shareholders elected eight directors to serve until the next annual meeting and until their successors are duly elected and qualified. Our shareholders also ratified the Board of Directors' selection of Rothstein, Kass & Company, P.C. as our independent public auditors to audit our financial statements for the current fiscal year. There were 33,996,017 outstanding shares of BioTime's common stock as of April 26, 2010 entitled to vote and 28,891,219 shares, or 84.98%, represented at the meeting, either in person or by proxy. The following tables show the votes cast by our shareholders and any abstentions and broker non-votes with respect to the matters presented to shareholders for a vote at the meeting:

Election of Directors

<u>Nominee</u>	<u>Votes For</u>	<u>Percent of Vote</u>	<u>Votes Withheld</u>
Neal C. Bradsher	19,028,087	99.84	29,828
Arnold I. Burns	19,019,240	99.80	38,675
Robert N. Butler	19,021,074	99.81	36,841
Abraham E. Cohen	19,021,895	99.81	36,020
Alfred D. Kingsley	19,029,855	99.85	28,060
Pedro Lichtinger	19,027,745	99.84	30,170
Judith Segall	19,029,251	99.85	28,664
Michael D. West	19,025,355	99.83	32,560

Ratification of Appointment of Independent Auditors

	<u>Shares Voted</u>	<u>Percent of Quorum</u>
For	28,840,146	99.82
Against	12,744	0.04
Abstain	38,329	0.13
Broker Non-Votes	0	0.00

Section 9 - Financial Statements and Exhibits

Item 9.01 - Financial Statements and Exhibits.

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press release dated June 14, 2010

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOTIME, INC.

Date: June 14, 2010

By: /s/ Steven A. Seinberg
Chief Financial Officer

Exhibit Number

99.1

Description

Press release dated June 14, 2010

BioTime Announces Results of Vote at Annual Shareholders Meeting**Annual Meeting Presentation Now Available on BioTime's Website**

ALAMEDA, Calif.--(BUSINESS WIRE)--June 14, 2010--BioTime, Inc. (NYSE Amex: BTIM) announced today that all of the nominees for election to the BioTime Board of Directors were re-elected by BioTime's shareholders at the 2010 Annual Meeting held on June 10. Each nominee received not less than 99.8% of the votes cast at the meeting. Our directors are Neal C. Bradsher, Arnold I. Burns, Robert N. Butler, Abraham E. Cohen, Alfred D. Kingsley, Pedro Lichtinger, Judith Segall, and Michael D. West. The shareholders, by a vote in excess of 99.8% in favor, also ratified the appointment of Rothstein, Kass & Company, P.C. to serve as BioTime's independent public auditors to audit BioTime's financial statements for the current fiscal year ending December 31, 2010.

At the meeting, BioTime CEO Dr. Michael West gave a corporate presentation updating investors on the company's technology and business activities. A video of this discussion entitled "Corporate Presentation at Annual Meeting of Shareholders 2010" can be viewed at <http://www.biotimeinc.com/btvideo4.htm> or the Company's home page.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies are developed through subsidiaries focused on specific fields of applications. BioTime develops and markets research products in the field of stem cells and regenerative medicine through its wholly owned subsidiary Embryome Sciences, Inc. BioTime's subsidiary OncoCyte Corporation focuses on the therapeutic applications of stem cell technology in cancer. Another subsidiary, OrthoCyte Corporation, is developing therapeutic applications of stem cells to treat orthopedic diseases and injuries. BioTime plans to develop therapeutic products in China for the treatment of ophthalmologic, skin, musculo-skeletal system and hematologic diseases, including the targeting of genetically modified stem cells to tumors as a novel means of treating currently incurable forms of cancer through its subsidiary BioTime Asia, Limited. Our Singapore subsidiary, ES Cell International Pte Ltd, has been at the forefront of advances in human embryonic stem ("hES") cell technology, being one of the earliest distributors of hES cell lines to the research community. ESI has produced clinical-grade human embryonic stem cell lines that were derived following principles of good manufacturing practice and currently offers them for potential use in therapeutic product development. In addition to its stem cell products, BioTime develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, and technology for use in surgery, emergency trauma treatment and other applications. BioTime's lead product, Hextend®, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive licensing agreements. Additional information about BioTime, Embryome Sciences, OncoCyte, OrthoCyte, BioTime Asia, and ESI can be found on the web at www.biotimeinc.com.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: <http://www.b2i.us/irpass.asp?BzID=1152&to=ea&s=0>.

CONTACT:

BioTime, Inc.

Judith Segall, 510-521-3390, ext 301

jsegall@biotimemail.com